SG10201706760YA - Process for making benzoxazepin compounds - Google Patents
Process for making benzoxazepin compoundsInfo
- Publication number
- SG10201706760YA SG10201706760YA SG10201706760YA SG10201706760YA SG10201706760YA SG 10201706760Y A SG10201706760Y A SG 10201706760YA SG 10201706760Y A SG10201706760Y A SG 10201706760YA SG 10201706760Y A SG10201706760Y A SG 10201706760YA SG 10201706760Y A SG10201706760Y A SG 10201706760YA
- Authority
- SG
- Singapore
- Prior art keywords
- making
- benzoxazepin compounds
- compounds
- making benzoxazepin
- benzoxazepin
- Prior art date
Links
- ZCXLTWVZYXBHJS-UHFFFAOYSA-N 1,2-benzoxazepine Chemical class O1N=CC=CC2=CC=CC=C12 ZCXLTWVZYXBHJS-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361779619P | 2013-03-13 | 2013-03-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201706760YA true SG10201706760YA (en) | 2017-10-30 |
Family
ID=50241450
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201507394RA SG11201507394RA (en) | 2013-03-13 | 2014-03-12 | Process for making benzoxazepin compounds |
| SG10201706760YA SG10201706760YA (en) | 2013-03-13 | 2014-03-12 | Process for making benzoxazepin compounds |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201507394RA SG11201507394RA (en) | 2013-03-13 | 2014-03-12 | Process for making benzoxazepin compounds |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9303043B2 (en) |
| EP (3) | EP2970329A1 (en) |
| JP (6) | JP6363120B2 (en) |
| KR (3) | KR20180070715A (en) |
| CN (2) | CN105377856B (en) |
| AR (1) | AR095365A1 (en) |
| AU (3) | AU2014230812B2 (en) |
| BR (1) | BR112015020716A2 (en) |
| CA (6) | CA3005112A1 (en) |
| HK (1) | HK1215433A1 (en) |
| IL (1) | IL240793A0 (en) |
| MX (1) | MX2015011438A (en) |
| NZ (1) | NZ711192A (en) |
| RU (2) | RU2649976C2 (en) |
| SG (2) | SG11201507394RA (en) |
| WO (1) | WO2014140073A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112016009665A8 (en) | 2013-12-16 | 2020-04-07 | Hoffmann La Roche | polymorphs, pharmaceutical composition, processes for the preparation of a polymorph and uses of polymorphs |
| CN112062778B (en) | 2015-07-02 | 2024-04-19 | 豪夫迈·罗氏有限公司 | Benzoxazepine oxazolidinone compounds and methods of use thereof |
| CN111848643A (en) | 2015-07-02 | 2020-10-30 | 豪夫迈·罗氏有限公司 | Benzoxazepine compounds and methods of use thereof |
| CN105906635A (en) * | 2016-06-08 | 2016-08-31 | 上海大学 | Perfluoroalkyl benzo-azepino quinoxaline derivative and synthesis method thereof |
| CN114716377A (en) | 2016-07-29 | 2022-07-08 | 日本烟草产业株式会社 | Process for producing pyrazole-amide compound |
| TW201825465A (en) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | Phosphatidylinositol 3-kinase inhibitors |
| TW201813963A (en) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | Phosphatidylinositol 3-kinase inhibitors |
| TW201815787A (en) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | Phosphatidylinositol 3-kinase inhibitors |
| ES2953833T3 (en) | 2016-12-15 | 2023-11-16 | Hoffmann La Roche | The invention relates to methods of preparing benzoxazeppine oxazolidinone compounds and useful intermediates. |
| CN108752237A (en) * | 2018-07-05 | 2018-11-06 | 四川青木制药有限公司 | A kind of new preparation process of p-amino-benzamidine hydrochloride |
| US20220040324A1 (en) | 2018-12-21 | 2022-02-10 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and kinase inhibitor |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9208135D0 (en) | 1992-04-13 | 1992-05-27 | Ludwig Inst Cancer Res | Polypeptides having kinase activity,their preparation and use |
| US5846824A (en) | 1994-02-07 | 1998-12-08 | Ludwig Institute For Cancer Research | Polypeptides having kinase activity, their preparation and use |
| US6274327B1 (en) | 1992-04-13 | 2001-08-14 | Ludwig Institute For Cancer Research | Polypeptides having kinase activity, their preparation and use |
| ES2205944T3 (en) * | 1998-10-23 | 2004-05-01 | Dow Agrosciences Llc | COMPOUNDS OF 3- (REPLACED PHENYL) -5- (REPLACED CYCLOPROPIL) -1,2,4-TRIAZOL. |
| EP1409125B1 (en) | 2001-07-12 | 2016-04-20 | Reaxa Limited | Microencapsulated catalyst, methods of preparation and methods of use thereof |
| CA2463441A1 (en) * | 2001-10-12 | 2003-05-08 | Bayer Pharmaceuticals Corporation | Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity |
| EP1945222B1 (en) | 2005-11-02 | 2012-12-26 | Bayer Pharma Aktiengesellschaft | Pyrrolo[2,1-f] [1,2,4]-triazin-4-ylamines as igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases |
| PL2081937T3 (en) | 2006-10-23 | 2013-01-31 | Sgx Pharmaceuticals Inc | Triazolopyridazine protein kinase modulators |
| ES2393130T3 (en) * | 2006-10-23 | 2012-12-18 | Sgx Pharmaceuticals, Inc. | Bicyclic triazoles as protein kinase modulators |
| ES2531002T3 (en) | 2007-01-19 | 2015-03-09 | Xcovery Inc | Kinase Inhibitor Compounds |
| WO2009055730A1 (en) * | 2007-10-25 | 2009-04-30 | Genentech, Inc. | Process for making thienopyrimidine compounds |
| ES2556353T3 (en) * | 2008-02-21 | 2016-01-15 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
| CL2009000780A1 (en) | 2008-03-31 | 2010-01-15 | Genentech Inc | Substituted heterocyclyl-pyran-heterocyclyl, heterocyclyl-oxepine-heterocyclyl, benzopyran-heterocyclyl and substituted benzoxepine-heterocyclyl derived compounds; pharmaceutical composition; process for preparing the composition; pharmaceutical kit; and its use in the treatment of cancer, mediated by the inhibition of pi3k. |
| GB0810902D0 (en) | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
| PE20121025A1 (en) | 2009-09-28 | 2012-08-06 | Hoffmann La Roche | BENZOXAZEPINE COMPOUNDS AS P13K INHIBITORS |
| JP5546636B2 (en) | 2009-09-28 | 2014-07-09 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Benzoxepin PI3K inhibitor compounds and methods of use |
| EP2493307B1 (en) * | 2009-10-29 | 2016-04-27 | Merck Sharp & Dohme Corp. | Bridged bicyclic piperidine derivatives and methods of use thereof |
| CN102558167A (en) * | 2010-12-29 | 2012-07-11 | 中国医学科学院药物研究所 | Thiazolidine derivant with GK and PPAR double excitation activity |
| CA2825966A1 (en) * | 2011-03-21 | 2012-09-27 | F. Hoffmann-La Roche Ag | Benzoxazepin compounds selective for pi3k p110 delta and methods of use |
| NO3175985T3 (en) * | 2011-07-01 | 2018-04-28 | ||
| NZ702244A (en) | 2012-06-08 | 2017-06-30 | Hoffmann La Roche | Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer |
-
2014
- 2014-03-12 AU AU2014230812A patent/AU2014230812B2/en not_active Ceased
- 2014-03-12 KR KR1020187016976A patent/KR20180070715A/en not_active Application Discontinuation
- 2014-03-12 CA CA3005112A patent/CA3005112A1/en not_active Abandoned
- 2014-03-12 CA CA3005118A patent/CA3005118A1/en not_active Abandoned
- 2014-03-12 CA CA2897618A patent/CA2897618A1/en not_active Abandoned
- 2014-03-12 EP EP14709314.0A patent/EP2970329A1/en not_active Withdrawn
- 2014-03-12 JP JP2015562108A patent/JP6363120B2/en active Active
- 2014-03-12 CN CN201480015055.8A patent/CN105377856B/en active Active
- 2014-03-12 BR BR112015020716A patent/BR112015020716A2/en not_active Application Discontinuation
- 2014-03-12 CA CA2948763A patent/CA2948763C/en not_active Expired - Fee Related
- 2014-03-12 CN CN201810489045.8A patent/CN108929333A/en active Pending
- 2014-03-12 KR KR1020157024484A patent/KR101821468B1/en active IP Right Grant
- 2014-03-12 EP EP20204345.1A patent/EP3845540A1/en active Pending
- 2014-03-12 AR ARP140100904A patent/AR095365A1/en unknown
- 2014-03-12 SG SG11201507394RA patent/SG11201507394RA/en unknown
- 2014-03-12 SG SG10201706760YA patent/SG10201706760YA/en unknown
- 2014-03-12 RU RU2015138488A patent/RU2649976C2/en not_active IP Right Cessation
- 2014-03-12 EP EP18173513.5A patent/EP3404032A3/en active Pending
- 2014-03-12 CA CA3005103A patent/CA3005103A1/en not_active Abandoned
- 2014-03-12 CA CA2948765A patent/CA2948765A1/en not_active Abandoned
- 2014-03-12 KR KR1020177016062A patent/KR101871133B1/en active IP Right Grant
- 2014-03-12 US US14/205,634 patent/US9303043B2/en active Active
- 2014-03-12 MX MX2015011438A patent/MX2015011438A/en unknown
- 2014-03-12 NZ NZ711192A patent/NZ711192A/en not_active IP Right Cessation
- 2014-03-12 WO PCT/EP2014/054786 patent/WO2014140073A1/en active Application Filing
- 2014-03-12 RU RU2018109979A patent/RU2018109979A/en not_active Application Discontinuation
-
2015
- 2015-08-24 IL IL240793A patent/IL240793A0/en unknown
-
2016
- 2016-03-23 HK HK16103386.8A patent/HK1215433A1/en unknown
- 2016-06-28 AU AU2016204432A patent/AU2016204432B2/en not_active Ceased
-
2017
- 2017-07-10 JP JP2017135083A patent/JP6442005B2/en active Active
-
2018
- 2018-02-27 AU AU2018201393A patent/AU2018201393A1/en not_active Abandoned
- 2018-03-12 JP JP2018044050A patent/JP2018150298A/en active Pending
- 2018-08-16 JP JP2018153231A patent/JP6663459B2/en active Active
- 2018-11-22 JP JP2018219226A patent/JP2019089762A/en active Pending
-
2020
- 2020-02-28 JP JP2020032846A patent/JP2020114814A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201311910D0 (en) | Novel Compounds | |
| GB201311888D0 (en) | Novel compounds | |
| HK1215433A1 (en) | Process for making benzoxazepin compounds | |
| IL243207B (en) | Process for manufacturing 4 -propargylated amino-benzoxazinones | |
| GB201317363D0 (en) | Novel compounds | |
| HK1244272A1 (en) | Process for making thienopyrimidine compounds | |
| GB201318222D0 (en) | Novel compounds | |
| GB201314926D0 (en) | Novel Compounds | |
| IL245543B (en) | Process for fluorinating compounds | |
| IL241287A0 (en) | Processes for producing sovaprevir | |
| IL245542B (en) | Process for fluorinating compounds | |
| GB201415000D0 (en) | Improved process | |
| GB201320021D0 (en) | Novel Compounds | |
| EP2971018A4 (en) | Barley-based biorefinery process | |
| EP2970113A4 (en) | Novel compounds | |
| GB201316764D0 (en) | Novel compounds | |
| GB201316762D0 (en) | Novel compounds | |
| GB201306308D0 (en) | Novel process | |
| IL244646B (en) | Process for preparing 5-fluoro-1-alkyl-3-fluoroalkyl-1h-pyrazole-4-carbaldehyde | |
| IL239993A (en) | Process for preparing 5-fluoro-1-methyl-3-difluoromethyl-1h-pyrazole-4-carbaldehyde | |
| GB201307314D0 (en) | Process for preparing chemical compounds | |
| GB201321975D0 (en) | Novel compounds | |
| GB201321972D0 (en) | Novel compounds | |
| GB201321976D0 (en) | Novel compounds | |
| GB201321811D0 (en) | Novel compounds |